List of Artificial Intelligence Companies in India - 17

Algorithmic Biologic's vision is to create a bountiful and healthy world by bringing scale efficiencies to molecular discovery and diagnostics. Our transdisciplinary team has a deep modeling-based understanding of the chemistry and mechanics of molecular technologies. Our first product, Tapestry, is award-winning, regulatory approved algorithmic solution to provide affordable large-scale COVID-19 testing.

Later part of the bygone twentieth century has witnessed a major revolution in the field of life-sciences. Researches carried out during this period, particularly in the area of molecular biology and recombinant technology, have led to emergence of 'Biotechnology'​ with a new face. Plants, animals and microorganisms being a key component of our ecosystem have always remained at centre-stage of research for different purposes as they affect the human life. Development of culture methods, better understanding about molecular biology, discovery of restriction endonucleases and their use in mapping of DNA laid the foundation stone for modern day biotechnology. Isolation of thermostable DNA polymerase along with the development of PCR technique made cloning simplified and providing way for rec-DNA technology. Further developments were generation of bar-code like DNA fragment patterns of genomic DNA. These patterns appeared useful in distinguishing individuals based on DNA sequence variations among them. Such variations of DNA among organisms were termed as fingerprints or profiles which provide a versatile tool to characterize genetic variability, genome evolution, population genetics, taxonomy, breeding and diagnostics even today! The technology to read the DNA base-by-base made it possible to identify useful genes. This information which could be cloned in suitable vectors and introduced in appropriate hosts through a variety of gene transfer methods gave an impetus to genetic improvement programmes and production of Genetically modified organisms. Today the genomic sequencing is contributing to identify the basis of pathology, providing tailored therapies. We are quickly advancing towards the in situ engineering of the genomic information to achieve designer humanity. Bioheaven ventures into this space "Turning Human Needs into Careful Solutions"​..........

Cardiotrack is a disruptive healthcare diagnostics solution that is making healthcare delivery more efficient. The mission of Cardiotrack is to reduce the cost of diagnosis by an order of magnitude through innovation in product design, and enhancements in healthcare workflow. Key challenges faced by healthcare providers include – the high cost of diagnostic equipment and lack of trained professionals, especially in semi-urban areas. Cardiotrack is addressing both these issues through the state of the art medical electronics, data analytics, cloud storage and diagnostics workflow management. Cardiotrack focuses on heart health and has consulted with some of the best medical research institutions in India like St John's Research Institute & Jayadeva Institute of Cardiovascular Science in Bangalore; brought onboard doctors and cardiologists as advisers and is collaborating researchers at the Loyola University of Chicago to deliver a comprehensive diagnostics solution for cardiovascular diseases (CVD). Cardiotrack is a multiple parameter handheld diagnostic device including 12-lead ECG monitor, pulse oximeter and blood pressure monitor integrated with mobile-based practice management solution and cloud backend. Low cost, portability and network-connectivity mean that Cardiotrack may be deployed at the primary care level and the resultant scan of the patient can be delivered instantaneously to a specialist anywhere in the world. This approach leads to efficient use of specialists'​ time, enables early diagnosis of heart patients and thus reduces the need for expensive invasive intervention. YouTube: https://www.youtube.com/watch?v=Tj3EI2iC7RE

CELLIX BIO - Founded in 2014, we are the leading drug discovery and development company. We generate our own drug design data before combining the critical power of AI with the creativity of involving proprietary platform technology, Synergix AI, and the expertise of our world-class scientists. This allows us to shorten the pre-clinical drug discovery stage and, in turn, substantially accelerate the delivery of new treatments to patients worldwide. By reducing the number of compounds analysed, we aim to vividly reduce the time and cost of discovering and developing new medicines. Cellix Bio balances Synergix AI plus human creativity in drug discovery.

Recognized as the 'Most Innovative Biotech Company, 2024', by Fast Company! Even today Early R&D, Precision Diagnostics and Translational Biomarker teams spend about 80% of their time wrangling data. Elucidata's mission is to empower scientists in the life sciences field by reclaiming every valuable hour for their research endeavors. Elucidata’s data harmonization platform - Polly, helps research teams make multi-modal biomedical data Machine Learning ready. Each dataset on Polly is processed consistently using pipelines of your choice, is custom curated with granular annotations and undergoes robust QA/QC checks to ensure highest data quality standards. Polly transforms multi-modal and multi-source biomedical data (Omics, Assay, Real World Data, Clinical & EHR Data, and CRO data) into a Unified Data Model. With our 10X faster LLM-powered curation and human-in-the-loop model to achieve 99.99% accuracy, we are fast-tracking time to analysis. Today, Polly is facilitating use case like patient stratification, biomarker discovery, target ID & validation, data management, and development of clinical and commercial pipelines across Pfizer, Janssen Pharmaceuticals, NextGen Jane and IMBDx and over 35 premier biopharma companies and research labs. Head-quarted in San Francisco, we are a 120+ multi-disciplinary team of experts based across the US and India. In September 2022, we raised $16 million in our Series A round led by Eight Roads and F-Prime along with our existing investors Hyperplane and IvyCap. Write to us at info@elucidata.io for queries To talk to us, visit: https://www.elucidata.io/book-a-meeting For more information, visit: https://www.elucidata.io/ Visit Our Offices - San Francisco Head Quarters: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Boston Office: 625 Massachusetts Avenue Cambridge, MA 02139 R&D Hubs, India - Delhi and Bangalore

Gennova Biopharmaceuticals Ltd. is a biotechnology company based in Pune, Maharashtra, India. The company specializes in the research, development, production, and commercialization of biotherapeutics and vaccines aimed at treating life-threatening diseases in areas such as cardiovascular, neurology, nephrology, and oncology. Gennova employs advanced recombinant DNA technologies and innovative bio-manufacturing practices to create effective biotherapeutic solutions. The company utilizes various expression platforms, including bacterial, mammalian, and yeast-based systems, to produce its recombinant products. Gennova has successfully commercialized seven products, including Tenectase, a biosimilar for treating Acute Ischemic Stroke, and HAMSYL, a treatment for acute lymphoblastic lymphoma offered at a lower price point for better accessibility. With a strong focus on research and development, Gennova is recognized as a preferred partner in the vaccine sector for research and cGMP manufacturing. The company employs around 598 people and has reported a revenue of $2.8 million, positioning itself as a notable player in the Indian biotechnology landscape.

Mapmygenome™ uses genomics to personalize health and well-being. Our at-home DNA tests and diagnostic genomic tests provide DNA-based insights that enable consumers, physicians, and health service providers to create a personalized health journey. Established in 2013, Mapmygenome™ has a vision to “Touch 100 million lives and save a million lives by 2030. Some of the preventive genomic tests that Mapmygenome™ offers are Genomepatri, BeautyMap, MyFitGene, Cardiomap, MedicaMap, and MapmyBiome. MapMyGenome also helps people discover their ethnic roots with Genomepatri Heritage.

With over two decades of experience in Big Data and Data Science Solutions, Molecular Connections (MC) has been using AI-powered proprietary models to help customers achieve digital transformation. We have been able to successfully build a data-driven decision-making strategy for our customer’s digital transformational journey. MC leverages AI, ML and the Linked Data Store to build efficiencies in various verticals and generate new revenue streams for its customers. MC’s decades of industry presence and a strong focus on innovation have led us to work with the world’s leading pharma and STEM industries to offer end-to-end software development and data insights powered by proprietary workflows and platforms, enabling content engineering across multiple domains. With over 70% of its workforce being women, MC is ranked among the top 15 best companies for women to work for in India. Subsidiary Companies: 1. Molecular Connections Analytics Pvt. Ltd. | URL: https://mcanalytics.co.in/ 2. Molecular Connections Research Pvt. Ltd. | URL: https://mcresearch.co.in/

We are Nexstem. We create Brain-Computer Interface (BCI) solutions that help people interact with technology using their brain signals. Founded in 2020, by Siddhant and Deepansh - engineers with a passion for neuroscience and technology, we've been pushing the boundaries of what's possible in neurotech since our first product, the Nexstem V1 in 2022. At Nexstem, we specialize in non-invasive BCI devices, like our 19-channel headset, Instinct, which comes with a full software ecosystem to decode brain signals. Our goal is to make BCI technology accessible, empowering researchers, clinicians, and developers to innovate and explore new frontiers in brain-computer interaction. Nexstem's technology is recognised by many stalwarts of the industries includes Mircrosoft for Startups, NASSCOM, VIVA tech Paris, YourStory and many more. We have got support from some of the finest neuroscientists and doctors to build accessible tech for the neurotech. We strongly believe in creating value for people and NeuroTech Pulse is our monthly news letter that highlights a news round-up of neurotech industry across the globe, events, case studies and individual spotlights for notable achievers in the field. Do join us on substack - nexstem.substack.com

OneCell Diagnostics, Inc. is a Precision Oncology Liquid Biopsy Diagnostics Company focused on developing the 1st-in-Class, Circulating Tumor Cell (CTC)-based, Single-Cell Multi-omics Lab Developed Tests for applications in clinical cancer care & early-stage clinical trials for Biotech/Pharma companies. ​ OneCell Diagnostics, Inc. is a joint venture between two companies with innovative technologies: Actorius Innovations and Research Pvt Ltd, a leading provider of CTC Tests in India, and Indx.ai, a Silicon Valley based innovative software company specialising in Multi-omics Biomarker Data Analytics.

PopVax is an Indian biotechnology company based in Hyderabad building a novel thermostable, low-cost, and safe second-generation mRNA platform for rationally-designed broadly-protective multi-epitope vaccines. We're starting with an open-source 4-8 °C refrigerator-stable booster candidate that is intended to protect against the entire sarbecovirus sub-family, including current and future strains of SARS-CoV-2 (the virus which causes COVID-19), and some other beta-coronaviruses such as MERS-CoV. PopVax's work has been funded primarily via collaboration with the Bill & Melinda Gates Foundation (India) and Vitalik Buterin's Balvi. Our India-based team of 30 researchers and senior manufacturing leaders includes experts in antigen design, mRNA sequence optimization and synthesis, and nucleic acid delivery from top Indian and North American research institutions, including CCMB, CDFD, IIT Delhi, IAVI, Harvard, Scripps, and UBC, as well as vaccine & biologics production veterans from companies including Sanofi, Biocon, Panacea Biotec and Biological E. The smaller scientific team for our US-based subsidiary, PopVax North America, is led by Moderna's first Director of Chemistry, and includes several leading practitioners of de novo computationally-driven rational protein design for novel vaccine immunogens.

Prantae is the vision of what lies beyond the boundaries of human imagination. It is a leap-of-faith into 'tomorrow of connected technologies' that empowers each one of the human kind to take control his own health and well-being. It is the canvas of every creative scientist, engineer and doctor who desire to change the face of humanity for better wherever in the galaxy humans ever venture to

Qure.ai is a breakthrough Artificial Intelligence (AI) solution provider that is disrupting the radiology 'status quo' by enhancing imaging accuracy and providing AI assistance for Accelerated Healthcare. The company uses deep learning and AI to make healthcare more accessible and equitable for patients. Qure AI also provides automated interpretation of radiology exams and ultrasound scans, and has raised a total funding of $56M over 5 rounds from healthcare investors.

RenaissThera is a pharmaceutical company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms. Our goal is to innovate for underserved populations and bridge the gaps in novel therapy access worldwide. We focus on high-unmet-need areas of prevalent diseases in cardio-metabolic therapy including diabetes type 2 and obesity. Leveraging our Innovation Platform powered by GenAI tools, we identify small-molecule therapies for proven pathways, ensuring cutting-edge solutions for patients. With a leadership team and scientific advisory board boasting extensive experience in global pharmaceutical product development, RenaissThera is committed to bringing innovative treatments to those in need around the world.

Transcell Biologics is an innovative biotech company with continuous discovery and process development as it's central theme to deliver unique disruptive stem cell based solutions to treat chronic and debilitating diseases that have otherwise no options available to manage. The passionate leadership team is committed to developing therapies to address important medical needs through adult stem cell technologies by collaborating with clinicians and patient communities. Among the company's landmark innovations is the development of a novel proprietary process for maximizing the therapeutic stem cell yield that also maintains the native pluripotent properties and inherent functionality. The Company has evolved from solely an R&D-focused biotech entity diversifying based on the intended applications of stem cell technologies.

Burden of medicine bills is a leading cause of financial worry among Indian consumers ● 70% of healthcare spend in India is on Medicines ● 15-20% of family income of chronic patients is spent on medicines ● 63 million people in India plunge into poverty annually due to healthcare costs Our vision is to make healthcare affordable and accessible to all. We are a technology driven, tele-health platform that aims to reduce healthcare expenses and improve healthcare outcomes by democratising medicine purchase in India. Truemeds, through its proprietary algorithm and tele-consultation, is able to recommend best value medicines to customers with precise scientific matching and outcomes history leading up to 51% savings for customers! We have grown at a phenomenal pace with customer love – 60X growth delivered in last 20 months. Headquartered in Mumbai, we are excited to build a strong product and operations team, which is passionate to build innovative solutions and willing to go the extra mile to ensure the customer has the best experience.

Vgenomics is an Indian company that aims to diagnose rare diseases with bioinformatics and artificial intelligence (AI). They are committed to addressing rare diseases and improving patient outcomes by analyzing complex genetic information. Vgenomics develops diagnostic and therapeutic solutions for inborn diseases, leveraging genomics and AI to bring novel solutions to the market for over 175 million children suffering from rare diseases.